GO
| HSI1 | 25,063.71 | 0.00 | -- |
| HSCEI1 | 8,499.53 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-03-24 10:13:22 SINOPHARM (01099.HK) management said at the results meeting that this year's pharmaceutical distribution business is expected to remain flat YoY, while the distribution and retail business of medical devices will further recover to positive growth, according to Citi's research report. In addition, SINOPHARM will be positioned as the cornerstone of Sinopharm Group's "1+4+x" strategy. While emphasizing its foundational role in the healthcare ecosystem, it plans to transform its business model to provide more comprehensive services across the entire value chain, support the launch of innovative drugs, speed up hospital access, and offer services for branded drugs outside the centralized procurement scope. Citi has lowered its target price from HKD23 to HKD22.8 but kept the Buy rating unchanged. ~ AAStocks Financial News Web Site: www.aastocks.com | |